This is a StreetInsider.com Premium Only Page

Merck (MRK) – Business Wire

Apr 17, 2024 08:00 AM MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour

Apr 16, 2024 08:00 AM MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing

Apr 4, 2024 06:45 AM Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metasta

Apr 3, 2024 08:00 AM REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Apr 1, 2024 06:45 AM Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25

Mar 28, 2024 06:45 AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Ca

Mar 26, 2024 06:21 PM FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)

Mar 21, 2024 06:45 AM Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Can

Mar 20, 2024 11:03 AM MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea

Mar 19, 2024 09:00 AM Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Mar 15, 2024 06:45 AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Can

Mar 13, 2024 03:00 AM Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Mar 11, 2024 08:15 AM Merck Completes Acquisition of Harpoon Therapeutics, Inc.

Mar 6, 2024 10:25 AM Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Mar 5, 2024 06:45 AM Merck to Participate in the Barclays 26th Annual Global Healthcare Conference

Mar 4, 2024 06:45 AM Merck to Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 29, 2024 08:00 AM EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits

Feb 27, 2024 07:00 AM Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024 06:45 AM Merck to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 23, 2024 06:20 AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment

Feb 20, 2024 06:45 AM FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Feb 5, 2024 06:33 AM Merck Animal Health to Acquire Elanco’s Aqua Business

Feb 1, 2024 06:30 AM Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Jan 27, 2024 10:00 AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephr

Jan 26, 2024 10:00 AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced

Jan 23, 2024 02:44 PM Merck Announces Second-Quarter 2024 Dividend

Jan 22, 2024 05:00 PM Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Jan 19, 2024 06:45 AM Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1

Jan 12, 2024 05:30 PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Jan 8, 2024 07:30 AM Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

Jan 5, 2024 06:45 AM Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline

Jan 4, 2024 08:00 AM Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

Jan 3, 2024 06:45 AM Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 22, 2023 08:00 AM Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Dec 20, 2023 04:30 PM Merck Provides U.S. Regulatory Update on Gefapixant

Dec 20, 2023 06:45 AM Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference

Dec 19, 2023 06:45 AM FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults

Dec 18, 2023 06:45 AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (C

Dec 15, 2023 05:00 PM FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Ca

Dec 14, 2023 07:00 PM FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI

Dec 11, 2023 06:45 AM Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected N

Dec 11, 2023 06:45 AM Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs

Dec 8, 2023 06:45 AM Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Dec 7, 2023 06:45 AM Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility

Dec 7, 2023 06:00 AM Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung

Nov 30, 2023 05:00 PM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic

Nov 29, 2023 09:00 AM AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development

Nov 28, 2023 01:17 PM Merck Announces First-Quarter 2024 Dividend

Nov 28, 2023 06:45 AM Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV

Nov 21, 2023 06:45 AM Merck to Acquire Caraway Therapeutics, Inc.